Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options (Q38818675)

6 September 2017

1 reference

title

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options (English)

1 reference

6 September 2017

Mª Luisa Isidro

1

1 reference

PMCID

3991023

6 September 2017

Fernando Cordido

series ordinal

2

1 reference

6 September 2017

12 January 2010

1 reference

6 September 2017

1 reference

6 September 2017

3

1 reference

6 September 2017

1

1 reference

6 September 2017

125-145

1 reference

Creative Commons Attribution 4.0 International

6 September 2017

start time

12 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Anti-obesity agents: a focused review on the structural classification of therapeutic entities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

A critical review of the cannabinoid receptor as a drug target for obesity management

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

The endocannabinoid system and energy metabolism

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

The satiety hormone peptide YY as a regulator of appetite.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

CNTF: a target therapeutic for obesity-related metabolic disease?

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Gut hormones as potential new targets for appetite regulation and the treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Mitochondrial uncoupling as a target in the treatment of obesity.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Neuropeptide y receptor selective ligands in the treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Effects of pro-opiomelanocortin (POMC) on food intake and body weight: mechanisms and therapeutic potential?

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

gp130 receptor ligands as potential therapeutic targets for obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Thermogenic and metabolic antiobesity drugs: rationale and opportunities

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Opportunities and challenges for the development of pharmacological therapies for obesity treatment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Gastrointestinal regulation of food intake

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Emerging therapeutic strategies for obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Gut peptides in the regulation of food intake and energy homeostasis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Vaccination against weight gain

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Investigational therapies in the treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Gut peptides and the regulation of appetite.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Safety of drug therapies used for weight loss and treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Meta-analysis: pharmacologic treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Glucagon-like peptide 1(GLP-1) in biology and pathology

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Gut hormone PYY(3-36) physiologically inhibits food intake

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

beta(3)-Adrenoceptor agonists: potential, pitfalls and progress

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Glucagon-like peptide-1: a potent regulator of food intake in humans

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Targeted disruption of the melanocortin-4 receptor results in obesity in mice

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Identification of targets of leptin action in rat hypothalamus

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Development of a pharmacologically improved peptide agonist of the leptin receptor

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.

17 June 2018

1 reference

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

21 January 2018

1 reference

Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands

21 January 2018

1 reference

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

21 January 2018

1 reference

Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus.

21 January 2018

1 reference

Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis.

21 January 2018

1 reference

Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure.

21 January 2018

1 reference

Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis

21 January 2018

1 reference

Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure

21 January 2018

1 reference

Food fails to suppress ghrelin levels in obese humans.

21 January 2018

1 reference

Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation

21 January 2018

1 reference

Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity

21 January 2018

1 reference

Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss

21 January 2018

1 reference

Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats.

21 January 2018

1 reference

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.

21 January 2018

1 reference

Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.

21 January 2018

1 reference

New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3991023

Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake

31 August 2018

1 reference

Oxyntomodulin suppresses appetite and reduces food intake in humans

21 January 2018

1 reference

12 December 2020

Ghrelin increases food intake in obese as well as lean subjects

1 reference

12 December 2020

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

1 reference

12 December 2020

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

1 reference

12 December 2020

Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients

1 reference

12 December 2020

Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects

1 reference

12 December 2020

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

12 December 2020

Bioactive enteroglucagon (oxyntomodulin): Present knowledge on its chemical structure and its biological activities

1 reference

12 December 2020

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

1 reference

12 December 2020

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in

1 reference

12 December 2020

Oxyntomodulin inhibits food intake in the rat

1 reference

12 December 2020

Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention

1 reference

12 December 2020

Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass

1 reference

12 December 2020

Novel analogs of ghrelin: physiological and clinical implications

1 reference

12 December 2020

Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults

1 reference

12 December 2020

Identifiers

DOI

10.3390/PH3010125

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

PMCID

3991023